Proteomics International is a pioneering medical technology company operating at the forefront of predictive diagnostics and bio-analytical services. The Company specializes in the area of proteomics – the industrial scale study of the structure and function of proteins.

Proteomics International’s aim is to use its expertise in proteins to develop and commercialize diagnostic tests for chronic diseases where there is unmet medical need. Some tests in the pipeline are Diabetic Kidney Disease, Endometriosis, Esophageal Cancer etc.

The Analytical Services component of Proteomics International is built around its proprietary technology platform. This centers upon the Company’s ISO 17025 laboratory accreditation for analytical services, which recognizes its ability to consistently achieve technically valid results and is the most widely used laboratory standard for US Federal testing laboratories.

Proteomics International is now registered as a Research Services Provider (RSP) with Australian Government vide reg. no. RSP000020 enabling eligible clients to claim tax incentives.

It has been serving local and international biotech, pharmaceutical industries and academia with its analytical capabilities in the following areas:

Pharmacokinetics- Bioanalytical testing
• Method Development & Validation
• Small Molecules & Peptides in Various Biological Matrices
• Quantitative Bioanalytics
• Non-Compartmental Analysis (WinNonlinTM)
Protein Analysis
• Biosimilar Characterisation
• Protein Sequencing, Physicochemical & Structure Analysis
• Food QC Testing -A2 Milk
Biomarker Services
• Protein Biomarker Discovery, verification, and validation
• Quantitative Differential Expression – iTRAQ/TMT
• Targeted Mass Spectrometry (MRM/SRM)